Ontorpacept

• Description:

  Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118) -fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity[1].

• Product Name Alternative:

  TTI-621

• UNSPSC:

  12352203

• Target:

  CD47

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ontorpacept.html

• Purity:

  99.57

• Solubility:

  10 mM in DMSO

• Smiles:

  [Ontorpacept]

• Molecular Weight:

  (76.43 kDa)

• References & Citations:

  [1]Petrova PS, et al. TTI-621 (SIRPαFc) : A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017 Feb 15;23 (4) :1068-1079.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 2

• CAS Number:

  2131089-46-6